Tag Archives: Cato BioVentures

Use A Detailed Development Plan to Secure Venture Capital

This is a guest post by Shane Grivna, Ph.D. Shane is a Clinical Strategy Scientist for Cato Research and an Analyst for Cato BioVentures. It’s a tough time to be asking for money.  Whether you’re a highschooler who needs cash … Continue reading

Posted in Guest Posts, Venture Capital | Tagged , , , , , , , | 1 Comment

Approval of Therapeutic Cancer Vaccines

This is a guest post by Laura DiMichele, Ph.D., R.A.C. Laura is a Clinical Strategy Scientist at Cato Research. Last month, Dendreon was granted approval for Provenge®, the first cell based cancer vaccine for treatment of asymptomatic or minimally symptomatic metastatic … Continue reading

Posted in FDA, Guest Posts, Industry News, Publications | Tagged , , , , , , , , , , , , , , , , , , , | 1 Comment

Cato at BIO 2010

The BIO International Convention is the largest global event for the biotechnology industry.  It attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.  This year’s … Continue reading

Posted in Conferences and Meetings | Tagged , , , , , , , , | Comments Off